Tuesday, December 15, 2020 12:31:45 PM
Widad Group collaborates with Rinani Dynamic to distribute, market and sell Vaxart’s Covid-19 vaccine tablet
https://www.thesundaily.my/business/widad-group-collaborates-with-rinani-dynamic-to-distribute-market-and-sell-vaxart-s-covid-19-vaccine-tablet-CI5648325
Widad is principally involved in construction activities and integrated facilities management services.
Rinani is the local representative in Malaysia for Nasdaq-listed Vaxart, with respect to its ongoing development of an oral based (tablet) Covid-19 vaccine named VXA-Cov2-1. The appointment of Rinani was made by Majoritas Global Limited, a company incorporated in Hong Kong, who in turn is Vaxart’s global representative for Malaysia.
VXA-CoV2-1 is a single-dose Covid-19 tablet vaccine candidate which Vaxart believes can be conveniently distributed and administered without the need for cold-chain storage and distribution.
Under the agreement, Rinani will be collaborating with Widad in the distribution, marketing and selling of the vaccine and other Vaxart products in Malaysia. Widad stated that it is ready to support Rinani Dynamics objective of ensuring that people of Malaysia would be among the first to receive Vaxart’s vaccine, when it receives the FDA and EUA clearance for commercialisation. The vaccine candidate is expected to be entering Phase II of clinical trials.
Widad managing director Datuk Mohd Rizal Mohd Jaafar said Widad is determined to support Rinani’s effort in pushing Vaxart’s vaccine in Malaysia, to ensure that the nation would have access to what could be the most practical and sustainable vaccine for a mass vaccination program.
“Vaxart’s vaccine’s two biggest merits is first, that it is designed to trigger mucosal immunity, which is the first line of defence against airborne viruses such as Covid-19, providing total protection from infection altogether and second, being in tablet form, makes it the most ‘user-friendly’ vaccine, creating a hassle free, painless experience, one which I feel the people would greatly appreciate and would be encouraged to take.”
Recent VXRT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 10:10:10 AM
- Vaxart Provides Business Update • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 10:02:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 10:03:24 AM
- Vaxart Announces $40 Million Underwritten Offering of Common Stock • GlobeNewswire Inc. • 06/13/2024 11:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:26:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:36:53 PM
- Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 06/13/2024 08:15:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:40:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:39:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:39:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:38:42 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/23/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:03:43 PM
- Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 08:01:00 PM
- U.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed Reactions • IH Market News • 05/13/2024 11:10:27 AM
- Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers • GlobeNewswire Inc. • 04/30/2024 12:00:39 PM
- Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 12:00:13 PM
- Vaxart Provides Business Update and Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:01:00 PM
- U.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices Climb • IH Market News • 03/14/2024 11:41:01 AM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM